Total Payments
$3,769
2024 Payments
$848.14
Companies
52
Transactions
193
Medicare Patients
11,845
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$3,752 (99.5%)
Education$17.34 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,752 | 191 | 99.5% |
| Education | $17.34 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $495.46 | 26 | $0 (2024) |
| PFIZER INC. | $365.95 | 23 | $0 (2024) |
| Allergan Inc. | $313.57 | 7 | $0 (2019) |
| Merck Sharp & Dohme LLC | $208.29 | 11 | $0 (2024) |
| Gilead Sciences, Inc. | $178.70 | 9 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $134.42 | 8 | $0 (2024) |
| Genentech USA, Inc. | $123.46 | 8 | $0 (2024) |
| Amgen Inc. | $120.51 | 7 | $0 (2022) |
| Daiichi Sankyo Inc. | $108.39 | 4 | $0 (2024) |
| Medtronic, Inc. | $107.39 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $848.14 | 36 | Gilead Sciences, Inc. ($85.70) |
| 2023 | $395.16 | 18 | Medtronic, Inc. ($107.39) |
| 2022 | $314.57 | 17 | Novartis Pharmaceuticals Corporation ($56.36) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $99.71 | 5 | E.R. Squibb & Sons, L.L.C. ($36.80) |
| 2019 | $567.19 | 28 | Novartis Pharmaceuticals Corporation ($156.86) |
| 2018 | $687.68 | 41 | PFIZER INC. ($93.48) |
| 2017 | $844.98 | 47 | Allergan Inc. ($172.09) |
All Payment Transactions
193 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.97 | General |
| 12/06/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $17.93 | General |
| Category: Oncology | ||||||
| 11/21/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: DESMOID TUMORS | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $30.86 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $31.73 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $25.34 | General |
| Category: Hematology/Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/30/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.15 | General |
| Category: Oncology | ||||||
| 09/19/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: Oncology | ||||||
| 09/12/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.10 | General |
| 08/29/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.32 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.92 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.95 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $33.84 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 08/01/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.91 | General |
| Category: Oncology | ||||||
| 07/12/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $25.52 | General |
| Category: HORMONE THERAPY | ||||||
| 06/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.54 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $31.38 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 2,180 | 116,699 | $1.5M | $333,070 |
| 2022 | 56 | 3,161 | 105,470 | $1.4M | $366,070 |
| 2021 | 56 | 3,148 | 106,242 | $1.5M | $432,040 |
| 2020 | 65 | 3,356 | 115,386 | $1.5M | $433,405 |
Total Patients
11,845
Total Services
443,797
Medicare Billing
$1.6M
Procedure Codes
215
All Medicare Procedures & Services
215 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 3,420 | $174,420 | $62,837 | 36.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 24 | 8,560 | $196,880 | $49,902 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 441 | $149,499 | $41,807 | 28.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 61 | 340 | $128,520 | $32,009 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 231 | 430 | $102,770 | $26,299 | 25.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 111 | 369 | $69,741 | $17,646 | 25.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 46 | 41,310 | $165,240 | $16,256 | 9.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 346 | 1,221 | $10,989 | $10,248 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 352 | 1,323 | $38,367 | $9,946 | 25.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 128 | $26,368 | $6,994 | 26.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 66 | 319 | $26,796 | $6,880 | 25.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 135 | 650 | $44,850 | $6,845 | 15.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 49 | $23,226 | $6,695 | 28.8% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 18 | 40,980 | $81,960 | $6,285 | 7.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $17,214 | $4,833 | 28.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 41 | 270 | $15,120 | $4,196 | 27.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 16 | 80 | $14,240 | $3,906 | 27.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 61 | 223 | $13,603 | $2,603 | 19.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 18 | $10,008 | $2,470 | 24.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $8,190 | $2,417 | 29.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 21 | $7,917 | $2,065 | 26.1% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 22 | 11,500 | $57,500 | $1,875 | 3.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 73 | $5,767 | $1,552 | 26.9% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 27 | 44 | $6,864 | $1,244 | 18.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 18 | $3,546 | $1,127 | 31.8% |
About Dr. Vu Ho, MD
Dr. Vu Ho, MD is a Hematology healthcare provider based in St Petersburg, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871574871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vu Ho, MD has received a total of $3,769 in payments from pharmaceutical and medical device companies, with $848.14 received in 2024. These payments were reported across 193 transactions from 52 companies. The most common payment nature is "Food and Beverage" ($3,752).
As a Medicare-enrolled provider, Ho has provided services to 11,845 Medicare beneficiaries, totaling 443,797 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 215 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location St Petersburg, FL
- Active Since 11/08/2005
- Last Updated 01/08/2026
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1871574871
Products in Payments
- BOTOX COSMETIC (Biological) $122.95
- OPDIVO (Biological) $121.09
- TASIGNA (Drug) $110.83
- IBRANCE (Drug) $108.12
- ENDOFLIP (Device) $107.39
- KISQALI (Drug) $101.50
- Bavencio (Biological) $101.46
- ELIQUIS (Drug) $100.06
- IMFINZI (Drug) $71.04
- Revlimid (Drug) $62.55
- XARELTO (Drug) $62.31
- KEYTRUDA (Biological) $60.61
- Perjeta (Biological) $59.95
- MEKINIST (Drug) $59.85
- LONSURF (Drug) $59.25
- Enhertu (Drug) $59.04
- ADCETRIS (Biological) $58.87
- Trodelvy (Drug) $58.49
- Nplate (Biological) $57.22
- GILOTRIF (Drug) $55.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.